Neonatal Abstinence Syndrome: A Targeted Review for Pharmacists CE Included
暂无分享，去创建一个
G. Walliser | K. Horton | Maria Laikos | Kayti Kintner | K. Fink | Kent Wilin | Sarah Kradel | Taylor Roberson | T. Maiers | J. Tran | K. Lindsley | K. Bellmann | Michael Rush | A. Skouby | Tara Tokar | Brooke Marlowe | Gabi Gegenheimer | T. Tokar
[1] A. Hauschild,et al. Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. , 2012, The Lancet. Oncology.
[2] J. Utikal,et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. , 2012, The New England journal of medicine.
[3] K. Flaherty,et al. Inhibition of mutated, activated BRAF in metastatic melanoma. , 2010, The New England journal of medicine.
[4] S. Ariyan,et al. Incidence of the V600K mutation among melanoma patients with BRAF mutations, and potential therapeutic response to the specific BRAF inhibitor PLX4032 , 2010, Journal of Translational Medicine.
[5] A. McMichael,et al. Solar Ultraviolet Radiation: Global burden of disease from solar ultraviolet radiation , 2006 .